慢性特発性便秘(CIC)治療薬の世界市場予測

Inkwood Researchが発行した調査報告書(INKW709036)
◆英語タイトル:Global Chronic Idiopathic Constipation Drug Market Forecast 2017-2025
◆商品コード:INKW709036
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2017年7月19日
◆ページ数:112
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Inkwood Research社の概要及び新刊レポートはこちらでご確認いただけます。

Inkwood Research社が出版した本調査レポートでは、慢性特発性便秘(CIC)治療薬の世界市場について調査・分析し、慢性特発性便秘(CIC)治療薬の世界市場動向、市場予測、セグメント別分析、主要地域別分析(アメリカ市場、ヨーロッパ市場、アジア市場)、世界市場規模、関連企業分析などを含め、以下の構成でお届けいたします。
【レポートの概要】

KEY FINDINGSGlobal Chronic Idiopathic Constipation drug market is estimated to grow at a CAGR of 6.43% during the forecast period of 2017-2025. The important drivers propelling the market growth are the modern dietary habits, rising elderly population and the improved and efficient drugs in the pipeline. Linaclotide is the major type of drug popular in this market.

MARKT INSIGHT
The CIC drug market is segmented based on drug types and also on the basis of prescription types. The drug types segment is further divided into:
• Lubiprostone
• Linaclotide
• Others
The prescription type segment is further divided into:
• Prescribed drugs
• Over the Counter drugs
An increasing demand for CIC drug from Asia-Pacific market coupled with the high unmet needs globally is providing the market with plenty of growth opportunities.

REGIONAL INSIGHTS
Geographically, the global CIC drug market is segmented into the following regions:
• North America – U.S. & Canada
• Asia Pacific – China, Japan, and RoAPAC
• Europe – UK, Germany, and RoE
• Rest of World – MENA and Latin America
The North America is touted to account for the largest share during the forecast period on account of its developed healthcare systems and medical devices industry. Approximately 28% of the population residing there suffer from CIC. The growing government initiatives in order to treat and to improve the healthcare segment of the society by providing latest technological and advance medical treatments are also aiding the market growth.

COMPETITIVE INSIGHTS
Advanced product launch is the key strategy adopted by the various market players of global CIC drug market. The other strategies include acquisition and mergers. For example, Roche holding Inc acquired Ariosa Diagnostics Inc, which provides non-invasive prenatal testing (NIPT) service using cell free DNA (cf-DNA) technology. Also, Allergan announced a collaboration with the company AstraZeneca in order to develop and commercialize ATM-AVI (aztreonam and avibactam) for antibiotic-resistant gram-negative infections. The other major players in the market include:
• Synergy Pharmaceuticals
• Pfizer
• Sucampo Pharmaceuticals Inc
• Ironwood Pharmaceuticals Inc
• GlaxoSmithKline
• Others

【レポートの目次】

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
4.5.3. INCREASING ELDERLY POPULATION
4.5.4. IMPROVED AND EFFICIENT DRUGS IN PIPELINE
4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
4.6. RESTRAINTS
4.6.1. SURGICAL TREATMENTS
4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. INCREASING DEMAND FOR CIC DRUG FROM APAC MARKET
4.7.2. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. SIDE EFFECTS OF CIC DRUGS
5. GLOBAL CIC DRUGS MARKET, BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. OTHERS
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
6. GLOBAL CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIER
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. GLOBAL CIC DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
8.1. NORTH AMERICA
8.1.1. US
8.1.2. CANADA
8.2. EUROPE
8.2.1. UK
8.2.2. GERMANY
8.2.3. REST OF EUROPE
8.3. ASIA PACIFIC
8.3.1. CHINA
8.3.2. JAPAN
8.3.3. REST OF ASIA PACIFIC
8.4. REST OF THE WORLD
8.4.1. MIDDLE EAST AND AFRICA
8.4.2. LATIN AMERICA
9. COMPANY PROFILES
9.1. ALLERGENS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. CHUGAI PHARMACEUTICAL
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. FERRING INTERNATIONAL CENTER S.A.
9.3.1. OVERVIEW
9.3.2. PRODUCTS PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.5. PFIZER
9.5.1. OVERVIEW
9.5.2. PFIZER PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. GLAXOSMITHKLINE
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. ROCHE HOLDING AG
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. SANOFI
9.8.1. OVERVIEW
9.8.2. PRODUCTS PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. BAYER AG
9.9.1. OVERVIEW
9.9.2. PRODUCTS PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MERCK SHARP & DOHME
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. ELI LILLY AND COMPANY
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. SALIX PHARMACEUTICALS LTD
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.13. SUCAMPO PHARMACEUTICALS INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.14. IRONWOOD PHARMACEUTICALS INC
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
9.15.1. OVERVIEW
9.16. DAIICHI SANKYO CO LTD
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.17. COSMO PHARMACEUTICALS SA
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.18. PROGENICS PHARMACEUTICALS INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.19. THERAVANCE BIOPHARMA INC
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS

TABLES LIST
TABLE 1 GLOBAL CIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION
TABLE 3 CONSTIPATION IN PARKINSON’S DISEASE
TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION
TABLE 5 GLOBAL CIC DRUGS MARKET BY DRUG TYPE 2014-2022($ MILLION)
TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 7 LUBIPROSTONE DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 8 PRODUCT PROFILE (LINACLOTIDE)
TABLE 9 LINACLOTIDE DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 10 PRODUCT PROFILE (BISACODYL)
TABLE 11 OTHERS DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 12 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 13 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 14 GLOBAL CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 15 GLOBAL PRESCRIBED CIC DRUGS MARKET, BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 16 LINZESS PRECAUTIONS AND SIDE EFFECTS
TABLE 17 GLOBAL OVER THE COUNTER CIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 18 NORTH AMERICA CIC DRUGS MARKET BY COUNTRY 2017–2025 ($ MILLION)
TABLE 19 U.S. CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 20 U.S. CIC DRUGS MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 21 CANADA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 22 CANADA CIC DRUGS MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 23 EUROPE CIC DRUGS MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 24 UK CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 25 UK CIC DRUGS MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 26 GERMANY CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 27 GERMANY CIC DRUGS MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 28 ASIA PACIFIC CIC DRUGS MARKET BY COUNTRY 2017-2025 ($ MILLION)
TABLE 29 CHINA CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 30 CHINA CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 31 JAPAN CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 32 JAPAN CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 33 REST OF WORLD CIC DRUGS MARKET, BY REGION, 2017-2025 ($ MILLION)
TABLE 34 MENA CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 35 MENA CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)
TABLE 36 LATIN AMERICA CIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 37 LATIN AMERICA CIC DRUG MARKET BY MAJOR DRUGS 2017-2025 ($ MILLION)

FIGURE LIST
FIGURE 1 GLOBAL CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 2 GLOBAL CIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
FIGURE 3 GLOBAL CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2016 ($ MILLION)
FIGURE 4 CAUSES OF CONSTIPATION
FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014
FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE
FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS
FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION
FIGURE 9 NEED OF SURGERY PROCESS
FIGURE 10 APAC CIC MARKET 2017-2025 ($ MILLION)
FIGURE 11 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM
FIGURE 12 GLOBAL LUBIPROSTONE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 13 GLOBAL LINACLOTIDE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 14 GLOBAL OTHER DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 15 GLOBAL PRESCRIBED CIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 16 GLOBAL OVER THE COUNTER CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 17 NORTH AMERICA CIC DRUGS MARKET 2017–2025 ($ MILLION)
FIGURE 18 US CIC MARKET, 2017-2025 ($ MILLION)
FIGURE 19 CANADA CIC MARKET 2017-2025 ($ MILLION)
FIGURE 20 EUROPE CIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 21 UK CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 22 GERMANY CIC DRUG MARKET, 2017-2025 $ MILLION)
FIGURE 23 REST OF EUROPE CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 24 ASIA PACIFIC CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 25 CHINA CIC DRUG MARKET 2017-2027 ($ MILLION)
FIGURE 26 COMPARISON OF PHARMACEUTICAL SALES ACROSS THE GLOBE
FIGURE 27 JAPAN CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 28 REST OF APAC CIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 29 MIDDLE EAST & AFRICA CIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 30 LATIN AMERICA CIC DRUG MARKET 2017-2025 ($ MILLION)



【レポートのキーワード】

慢性特発性便秘(CIC)治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 慢性特発性便秘(CIC)治療薬の世界市場予測(Global Chronic Idiopathic Constipation Drug Market Forecast 2017-2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆